禾元生物明日申购 顶格申购需配市值14万元

Company Overview - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [1] - The company plans to publicly issue 89.45 million shares, accounting for 25.02% of the total share capital post-issue [1] IPO Details - The subscription code for the IPO is 787765, with a subscription price set at 29.06 yuan per share [1] - The maximum subscription limit for a single account is 14,000 shares, requiring a minimum market value of 140,000 yuan in the Shanghai market [1] - The online issuance quantity is 14.31 million shares, with the subscription date on October 14, 2025, and the announcement of the winning numbers and payment date on October 16, 2025 [1] Fundraising Allocation - The company plans to allocate 1.90867 billion yuan for the construction of a plant-derived recombinant human serum albumin industrialization base [1] - An additional 793.69 million yuan is earmarked for new drug research and development [1] - 800 million yuan will be used to supplement working capital [1] Financial Performance - Total assets for 2024 are projected at 1.06181 billion yuan, an increase from 962.20 million yuan in 2023 [1] - Net assets are expected to decrease to 601.35 million yuan in 2024 from 731.62 million yuan in 2023 [1] - Operating revenue is forecasted to rise to 252.16 million yuan in 2024, compared to 242.64 million yuan in 2023 [1] - The company anticipates a net loss attributable to shareholders of 151.37 million yuan in 2024, an improvement from a loss of 186.96 million yuan in 2023 [1] - Research and development expenses are projected at 116.79 million yuan, representing 463.14% of operating revenue [1]